Abstract: Breast cancer (BRCA) remains the leading cause of cancer morbidity and mortality worldwide. In the present study, we identified novel biomarkers expressed during estradiol and tamoxifen treatment of BRCA. The microarray dataset of E-MTAB-4975 from Array Express database was downloaded, and the differential expressed genes (DEGs) between estradiol-treated BRCA sample and tamoxifen-treated BRCA sample were identified by limma package. The pathway and gene ontology (GO) enrichment analysis, construction of protein-protein interaction (PPI) network, module analysis, construction of target genes-miRNA interaction network and target genes-transcription factor (TF) interaction network were performed using bioinformatics tools. The expression, prognostic values, and mutation of hub genes were validated by SurvExpress database, cBioPortal, and human protein atlas (HPA) database. A total of 856 genes (421 up-regulated genes and 435 down-regulated genes) were identified in T47D (overexpressing Split Ends (SPEN) + estradiol) samples compared to T47D (overexpressing Split Ends (SPEN) + tamoxifen) samples. Pathway and GO enrichment analysis revealed that the DEGs were mainly enriched in response to lysine degradation II (pipecolate pathway), cholesterol biosynthesis pathway, cell cycle pathway, and response to cytokine pathway. DEGs (MCM2, TCF4, OLR1, HSPA5, MAP1LC3B, SQSTM1, NEU1, HIST1H1B, RAD51, RFC3, MCM10, ISG15, TNFRSF10B, GBP2, IGFBP5, SOD2, DHF and MT1H), which were significantly up-and down-regulated in estradiol and tamoxifen-treated BRCA samples, were selected as hub genes according to the results of protein-protein interaction (PPI) network, module analysis, target genes-miRNA interaction network and target genes-TF interaction network analysis. The SurvExpress database, cBioPortal, and Human Protein Atlas (HPA) database further confirmed that patients with higher expression levels of these hub genes experienced a shorter overall survival. A comprehensive bioinformatics analysis was performed, and potential therapeutic applications of estradiol and tamoxifen were predicted in BRCA samples. The data may unravel the future molecular mechanisms of BRCA.
Introduction
Breast cancer (BRCA) is the most common type of gynecological cancer in women [1] . BRCA accounts for 2,088,849 (11.6%)of new cancer cases [2] and 626,679 (6.6%) deaths in women worldwide, as per 2018 cancer statistics [3] .Surgical resection is an effective treatment to advance patient expression and low gene expression were compared by Kaplan-Meier survival plot, the log-rank p-value, and hazard ratio (HR, 95% confidence intervals). p < 0.05 is considered statistically significant.
Validation of Hub Genes
The mRNA expression of the DEGs was analyzed in 2 low-risk and 1 high-risk groups with the assistance of SurvExpress [53] , which is an online tool to deliver customizable functionalities based on The Cancer Genome Atlas, and the translational levels of the hub genes were validated using the Human ProteinAtlas (HPA) database [54] .
Mutation Analysis of Hub Genes
The cBio Cancer Genomics Portal [55] is a web tool, which provides mutation analysis, visualization, and downloads of cancer genomics datasets of various cancers. Complex cancer genomics profiles are accessible from the cBioPortal tool, thus enabling us to compare the genetic modifications of the selected ten hub genes in BRCA. The flowchart of the methodology is depicted below (Figure 1 ).
Figure 1.
The workflow representing the methodology and the major outcome of the study. BRCA-breast cancer, GO-gene ontology, miRNA-MicroRNA, TF-transcription factor, DEGs-differential expressed genes.
Results

Data Preprocessing
Before normalization, the medians of gene expression in each sample were greatly definite ( Figure 2A ). However, the medians became consistent and were at an identical level following normalization ( Figure 2B ), suggesting that the normalization process is valid, and the normalized data may be used for additional analysis. Based on their BRCA status, samples were divided into six groups: T47D (wild type genotype + estradiol) (n = 3), T47D (wild type genotype + none) (n = 3), T47D (wild type genotype + tamoxifen) (n = 3), T47D (overexpressing Split Ends (SPEN) + estradiol) (n = 3), T47D (overexpressing Split Ends (SPEN) + none) (n = 3), and T47D (overexpressing Split Ends (SPEN) + tamoxifen) (n = 3). 
Identification of DEGs
The DEGs of E-MTAB-4975 were analyzed using the limma package following preprocessing and removing batch effects. Using p < 0.05 and |logFC| > 1.19 as the cutoff criteria for up-regulated genes, p < 0.05 and |logFC)| > −1.35 for down-regulated genes, total of 856 genes (421 up-regulated genes and 435 down-regulated genes) were identified in T47D (overexpressing Split Ends (SPEN) + estradiol) samples compared to T47D (overexpressing Split Ends (SPEN) + tamoxifen) samples (Table S1 ). The DEGs (up-and down-regulated) are shown in the volcano plot ( Figure 3 ). The DEGs (up-and down-regulated), according to the value of |logFC|, are visualized on a heatmap (Figures 4  and 5) . A total of 145 housekeeping genes were identified in this dataset. Heat map of down-regulated differentially expressed genes. The legend on the top left indicates log fold change of genes. (A1, A2, A3 = T47D (wild type genotype + estradiol); B1, B2, B3 = T47D (wild type genotype + none); C1, C2, C3 = T47D (wild type genotype + tamoxifen); D1, D2, D3 = T47D (overexpressing Split Ends (SPEN) + estradiol); E1, E2, E3 = T47D (overexpressing Split Ends (SPEN) + none); F1, F2, F3 = T47D (overexpressing Split Ends (SPEN) + tamoxifen)).
Pathway Enrichment Analysis
The DEGs (up-and down-regulated) were uploaded to the online web tool ToppGene having different pathway databases, such as BioCyc [24] , KEGG [25] , PID [26] , Reactome [27] , GenMAPP [28] , MSigDB C2BioCarta [29] , PantherDB [30] , Pathway Ontology [31] , and SMPDB [32] . Tables S2 and S3 contain the most significantly enriched pathways for up-and down-regulated genes from different pathway databases. The up-regulated genes were enriched in lysine degradation II (pipecolate pathway), pyrimidine deoxyribonucleosides salvage, DNA replication, cell cycle, E2F transcription factor network, BARD1 signaling events, mitotic, pyrimidine metabolism, carbon pool by folate, CDK regulation of DNA replication, expression of cyclins regulating progression through the cell cycle by activating cyclin-dependent kinases, tetrahydrofolate biosynthesis, mismatch repair pathway, nucleotide excision repair, and GABA-transaminase deficiency, listed in Table S2 . The down-regulated genes were enriched in superpathway of cholesterol biosynthesis, cholesterol biosynthesis II (via 24,25-dihydrolanosterol), mineral absorption, squalene 2,3-epoxide => cholesterol, ATF-2 transcription factor network, direct p53 effectors, response to metal ions, sterol biosynthesis, gamma-hexachlorocyclohexane degradation, genes encoding secreted soluble factors, actions of nitric oxide in the heart, apoptosis signaling pathway, cholesterol biosynthetic, steroid biosynthetic, and risedronate pathway, listed in Table S3 .
Gene Ontology (GO) Enrichment Analysis
The DEGs were uploaded to the online web tool ToppGene to pinpoint overrepresented GO categories. GO analysis results showed that up-regulated genes were significantly enriched in all GO terms, which include: cell cycle, DNA replication, chromosome, chromosomal part, chromosome, centromeric region, and DNA helicase activity (Table S4) , while down-regulated genes were significantly enriched in all GO terms, which include: response to cytokine, cellular response to cytokine, endoplasmic reticulum, nuclear outer membrane-endoplasmic reticulum membrane network, cytokine activity, and cytokine receptor binding (Table S5) .
PPI Network Construction and Topology Analysis
The PPI network (up-regulated) had 6479 nodes and 15,710 interactions ( Figure 6 ). Hub genes with high node degree, such as MCM2 (degree = 875), CDK2 (degree = 737), BRCA1 (degree = 561), HIST1H3F (degree = 454), and HIST1H3B (degree = 454), are listed in Table S6 . R square = 0.773 and correlation coefficient = 0.987 for node degree ( Figure 7A ). Hub genes with high betweenness centrality, such as TCF4 (betweenness = 0.04852), ASPM (betweenness = 0.012646), CHST8 (betweenness = 0.005764), KCNB1 (betweenness = 0.004046), and CFH (betweenness = 0.003746), are listed in Table S6 . R square = 0.616 and correlation coefficient = 0.139 for betweenness centrality ( Figure 8A ). Hub genes with high stress, such as MCM2 (stress = 127048732), BRCA1 (stress = 87536324), CDK2 (stress = 84519756), HIST1H3F (stress = 47668690), and HIST1H3B (stress = 47668690), are listed in Table  S6 . R square = 0.000 and correlation coefficient = 0.039 for stress ( Figure 8B ). Hub genes with high closeness centrality, such as MCM2 (closeness = 0.414382), FLNA (closeness = 0.392197), BRCA1 (closeness = 0.398937), HIST1H3B (closeness = 0.388514), and HIST1H3F (closeness = 0.388514), are listed in Table S6 . R square = 0.286 and correlation coefficient = 0.400 for closeness ( Figure 8C ). Hub genes with low clustering coefficient, such as OLR1 (clustering coefficient = 0), CHST8 (clustering coefficient = 0), KLF8 (clustering coefficient = 0), CFH (clustering coefficient = 0), and XAGE2 (clustering coefficient = 0), are listed in Table S6 . R square = 0.476 and correlation coefficient = 0.803 for clustering coefficient ( Figure 8D ). The PPI network (down-regulated) had 5441 nodes and 9866 interactions ( Figure 9 ). Hub genes with high node degree, such as HSPA5 (degree = 572), MAPK6 (degree = 392), MAP1LC3B (degree = 375), SQSTM1 (degree = 308), and SDCBP (degree = 238), are listed in Table S6 . R square = 0.773 and correlation coefficient = 0.980 for node degree ( Figure 7B ). Hub genes with high betweenness centrality, such as MAP1LC3B (betweenness = 1.01E-01), SQSTM1 (betweenness = 9.98E-02), SDCBP (betweenness = 6.95E-02), ISG15 (betweenness = 5.19E-02), and ICAM1 (betweenness = 3.59E-02), are listed in Table  S6 . R square = 0.629 and correlation coefficient = 0.220 for betweenness centrality ( Figure 10A ). Hub genes with high stress genes, such as HSPA5 (stress = 144471588), MAPK6 (stress = 73838870), MAP1LC3B (stress = 51072854), SQSTM1 (stress = 39034828), and ICAM1 (stress = 38584000), are listed in Table S6 . R square = 0.042 and correlation coefficient = 0.206 for stress ( Figure 10B ). Hub genes with high closeness centrality, such as SQSTM1 (closeness = 0.369146), MAP1LC3B (closeness = 0.361868), MAPK6 (closeness = 0.345146), NDRG1 (closeness = 0.338184), and ISG15 (closeness = 0.336858), are listed in Table S6 . R square = 0.171 and correlation coefficient = 0.261 for closeness ( Figure 10C ). Hub genes with low clustering coefficient, such as NEU1 (clustering coefficient = 0), BRI3 (clustering coefficient = 0), SLC27A1 (clustering coefficient = 0), DDIT4 (clustering coefficient = 0), and CXCL1 (clustering coefficient = 0), are listed in Table S6 . R square = 0.540 and correlation coefficient = 0.874 for clustering coefficient ( Figure 10D ). 
Module Analysis
The PPI network (up-regulated genes) had 1835 modules. Module 15, module 23, module 44, and module 54 were highly significant ( Figure 11 ). Module 15 had 53 nodes and 148 edges. The hub genes, such as 
Construction of the Target Genes-miRNAInteraction Network
Target genes-miRNA interaction network (up-regulated) is shown in Figure 13 . Hub genes such as IGFBP5 interacts with 143 miRNAs, RAD51 interacts with 113 miRNAs, DSN1 interacts with 111 miRNAs, RRM2 interacts with102 miRNAs, and ZWINT interacts with 98 miRNAs (Table S7) . Target genes-miRNA interaction network (down-regulated) is shown in Figure 14 . Hub genes such as SOD2 interacts with 257 miRNAs, DNAJC10 interacts with 195 miRNAs, PEG10 interacts with 139 miRNAs, LDLR interacts with 123 miRNAs, and RORA interacts with 110 miRNAs (Table S7 ). 
Construction of the Target Genes-TF Interaction Network
Target genes-TF interaction network (up-regulated) is shown in Figure 15 . Hub genes such as DHF interacts with 178 TFs, TBXAS1 interacts with 177 TFs, MCEE interacts with 154 TFs, ETNK2 interacts with 144 TFs, and CENPM interacts with 137 TFs (Table S8) . Target genes-TF interaction network (down-regulated) is shown in Figure 16 . Hub genes such as MT1H interacts with 172 TFs, KRTAP5-4 interacts with 163 TFs, RETN interacts with 143 TFs, HSD17B14 interacts with 132 TFs, and SEPHS2 interacts with 124 TFs (Table S8 ). 
Survival Analysis of Hub Genes
To evaluate if the identified prognostic markers are valuable in predicting patient survival, we focused on the hub genes (up-and down-regulated genes). We utilized SurvExpress [54] , an online tool developed for conveniently exploring survival correlations with gene expression data from 502 cancer studies performed by The Cancer Genome Atlas (TCGA). Genes, such as BRCA1, FLNA, FLNB, HSPA5, MAP1LC3B, NDRG1, PCNA, and TUBB2B, which are overexpressed in BRCA, showed a positive correlation with patient survival. Patients with higher expression of these genes had favorable overall survival (p-value < 0.05) (Figure 17) . Genes, such as HIST1H3B and MAPK6, which are overexpressed in BRCA, showed a negative correlation with patient survival. Patients with higher expression of these genes had worse overall survival (p-value < 0.05) (Figure 18 ). . Kaplan-Meier survival curves using The Cancer Genome Atlas (TCGA) data validate the prognostic value of genes having worse overall survival in BRCA (Green-low expression; Red-high expression).
Validation of Hub Genes
The expression level of hub genes was assessed in 2 low-risk and1 high-risk groups. The data showed that the hub gene expression of BRCA1, HIST1H3B, MAPK6, NDRG1, and PCNA were increased (Figure 19 ), while that of FLNA, FLNB, HSPA5, MAP1LC3B, and TUBB2B were reduced (Figure 20 ) in the high-risk group compared with those in the low-risk group. The outcome of the validation of the hub genes on a translational level through the HPA database are displayed in Figure 21 .
Mutation Analysis of Hub Genes
The mutation analysis results made the ten hub genes we screened out reliable. As for genetic mutation, ten hub genes were altered in 98.6% of 1093 patients. Figure 22 depicts the alteration information of the ten hub genes. BRCA1, FLNA, FLNB, HIST1H3B, HSPA5, MAP1LC3B, MAPK6, NDRG1, PCNA, and TUBB2B were altered most often (4%, 3%, 2.4%, 2.9%, 2.2%, 3%, 2.3%, 12%, 1.1%, and 2.3%, respectively), and these include inframe mutation, missense mutation, truncating mutation, amplification, and deep deletion. Box plots of hub genes (BRCA1, HIST1H3B, MAPK6, NDRG1, and PCNA). Red-high-risk; Green-low-risk.
Figure 20.
Box plots of hub genes (FLNA, FLNB, HSPA5, MAP1LC3B, and TUBB2B). Red-high-risk; Green-low-risk. 
Discussion
Breast cancer is one of the most common cancer to affect women. BRCA is a heterogeneous disease presenting distinct subtypes (Triple Negative, Luminal A, Luminal B, human epidermal growth factor receptor (HER2+)). Increased estradiol level is associated with breast cancer development through regulation of the progesterone receptor [56, 57] . Estradiol antagonist tamoxifen has been the first line treatment for all stages of estrogen-receptor-positive BRCA [55] . In most cases, somatic mutations in breast cells acquired during a person's lifetime lead to breast cancer [58] . BRCA occurs due to the accumulation of different genetic mutations, thus, a high level of molecular heterogeneity in BRCA demands thorough investigation of the molecular markers and signaling pathways associated with pathogenesis of BRCA; this may be of benefit for the examination of targeted molecular therapy to assist early diagnosis and prognosis, and may also afford a molecular basis for treatment. In the current study, the integrated analysis was performed on the gene expression profiles in estradioland tamoxifen-treated BRCA cell lines. Using the microarray platforms, we identified 856 DEGs (421 up-regulated and 435 down-regulated). BRCA arises from the accumulation of different gene modifications, and it is important to characterize the genetic changes during the advancement of BRCA [59] . Methylation inactivation of tumor suppressor KCNB1 is responsible for the development of gliomas [60] , but this gene may be identified with the development of BRCA. COL12A1 is diagnosed with the pathogenesis of gastric cancer [61] , but this gene may be associated with the pathogenesis of BRCA. DIAPH3 is important for metastasis of hepatocellular carcinoma cells through stimulation of the beta-catenin/TCF signaling pathway [62] , but this gene may be linked with metastasis of BRCA. SFXN2 is important for the invasion of oral squamous cell carcinoma [63] , but this gene may be responsible for the invasion of BRCA cells. GLDC is involved in the pathogenesis of non-small cell lung cancer cell proliferation through pyrimidine metabolism [64] , but this gene may be linked with changes in amino acid and nucleic acid metabolism in BRCA. DDIT4 is liable for the proliferation of gastric cancer cell through activation of p53 and MAPK pathways [65] , but this gene may be associated with the proliferation of BRCA cells. Loss of genes, such as INSIG1 and ACSS2, is responsible for the advancement of gastric cancer [66, 67] , but inactivation of these genes may be linked with the development of BRCA. IFIT3 is responsible for inflammatory stimulus in pancreatic cancer [68] , but this gene may be associated with inflammation in BRCA. Methylation inactivation of tumor suppressor genes, such as FLCN [69] and DDIT3 [70] , is important for the development of many cancer, such as renal cancer and gastric cancer, but inactivation of these genes may be responsible for the advancement of BRCA. PRSS8 is liable for the development of ovarian cancer [71] , but this gene may identify with the pathogenesis of BRCA. Genes, such as KLF8 [72] , TCF4 [73] , H19 [74] , NEU1 [75] , CXCL1 [76] , TRIB3 [77] , FTL [78] , and UBE2L6 [79] , are responsible for the pathogenesis of BRCA.
In pathway enrichment analysis, lysine degradation II (pipecolate pathway), DNA replication, E2F transcription factor network, cell cycle, pyrimidine metabolism, CDK regulation of DNA replication, mismatch repair pathway, and pyrimidine metabolism are the most significant pathways for up-regulated genes. CRYM is responsible for the development of prostate cancer [80] [103] , are linked with the invasion of hepatocellular carcinoma cells, but these genes may be important for the invasion of BRCA cells. AJUBA is diagnosed with the growth of colorectal cancer through apoptosis inhibition [104] , but this gene may be responsible for the advancement of BRCA, through inhibition of apoptosis. Genes, such as MCM2 [105] [136] , and MSH6 [137] , are responsible for the pathogenesis of BRCA. MCM6, POLA1, RFC2, MND1, HIST2H3A, SYCE2, CDC45, HAUS8, HIST1H2BF, FBXL18, HIST1H4D, CENPM, GINS3, RMI2, GINS4, NDC1, KNTC1, GINS1, FBXO5, HIST1H3F, ZWINT, and CTPS1 are identified as novel molecular markers for the pathogenesis of BRCA in these pathways. While superpathway of cholesterol biosynthesis, mineral absorption, ATF-2 transcription factor network, cholesterol biosynthesis, sterol biosynthesis, genes encoding secreted soluble factors, and steroid biosynthesis are the most significant pathways for down-regulated genes. Genes, such as HMGCS1 and HMGCR, are associated with the proliferation of prostate cancer cell [138] , but these genes may be responsible for the proliferation of BRCA cells. Genes, such as HMOX1 [139] and VEGFB [140] , are important for the invasion of various cancer cells, such as bladder cancer and colorectal cancer, but these genes may be associated with the invasion of BRCA cells. Methylation inactivation in tumor suppressors genes, such as MT1M [141] , MT1H [142] , MT1X [143] , and HRK [144] , is responsible for the development of various cancers, such as prostate cancer, liver cancer, colorectal cancer, and gastric cancer, but loss of these genes may be linked with the pathogenesis of BRCA. FGF13 is responsible for chemoresistance in cervical cancer [145] , but this gene may be associated with drug resistance in BRCA. CCL20 is linked with the development of gastric cancer [146] , but this gene may be liable for the progression of BRCA. SNP in tumor suppressor genes, such as TNFSF10 [147] and TNFSF9 [148] , are identified with the pathogenesis of various cancers, such as ovarian cancer and hepatocellular carcinoma, but these polymorphic genes may be answerable for the development of BRCA. Genes, such as SQLE [149] [166] , LTB [167] , and S100A3 [168] , are responsible for the pathogenesis of BRCA. MSMO1, FDPS, IDI1, MVD, CYP51A1, DHCR7, LSS, BRCA, MT1A, MT1B, IL23A, and INHBE are identified as novel molecular markers for the pathogenesis of BRCA in these pathways.
In GO enrichment analysis, cell cycle, chromosome, and DNA helicase activity are the most significant GO terms for up-regulated genes. Genes, such as CHAF1B [169] , INHBA [170] , TGFB2 [171] , SKA3 [172] , and HELLS [173] , are responsible for the invasion of various cancer cells, such as hepatocellular carcinoma, gastric cancer cells, renal cell carcinoma, prostate cancer, head and neck cancer, but these genes may be involved in the invasion of BRCA cells. TRIP13 is responsible for the development of chemoresistance in head and neck cancer [174] , but this gene may be linked with the drug resistance in BRCA. DSCC1 is associated with the development of colorectal cancer through inhibition of apoptosis [175] , but this gene may be responsible for the inhibition of apoptosis in BRCA. SNP in tumor suppressor RAD54L is important for the development of pancreatic cancer [176] , but this polymorphic gene may be identified with the development of BRCA. Genes, such as CDCA3 [177] , KIF15 [178] , and TCF19 [179] , are linked with the proliferation of various cancer cells, such as oral cancer, pancreatic cancer, and hepatocellular carcinoma cells, but these genes may be responsible for the proliferation of BRCA cells. Genes, such as BOP1 [180] , KIF11 [181] , and MMS22L [182] , are associated with the progression of various cancers, such as colorectal cancer, gastric cancer, lung, and esophageal cancer, but these genes may be linked with the development of BRCA. Genes, such as PDGFB [183] , ANLN [184] , RECQL4 [185] , MKI67 [186] , FGFR2 [187] , FLNA [188] , DTL [189] , ID3 [190] , XRCC3 [191] , SIPA1 [192] , SPAG5 [193] , EGFL6 [194] , UHRF1 [195] , CTGF [196] , STARD13 [197] , RASSF2 [198] , PBK [199] , NEDD9 [200] , KIFC1 [201] , E2F8 [202] , THBS1 [203] , FANCI [204] , NUSAP1 [205] , SATB1 [206] , ASF1B [207] , and KDM4B [208] , are responsible for the pathogenesis of BRCA. FANCA, AUNIP, ASPM, DCLRE1B, PCLAF, CIT, HIST1H2AI, HIST1H2AL, ANKRD2, TONSL, WDHD1, and HIST1H1D are identified as novel molecular markers for the pathogenesis of BRCA in these GO categories.
While the response to cytokine, endoplasmic reticulum, and cytokine activity are the most significant GO terms for down-regulated genes. Genes, such as SERPINA3 [209] , BIRC3 [210] , and CREBRF [211] , are liable for the proliferation of various cancer cells, such as endometrial cancer and gastric cancer, but these genes may be linked with the proliferation of BRCA cells. Genes, such as IFIT2 [212] , CCR10 [213] , and TMEM97 [214] , are important for the invasion of various cancer cells, such as oral cancer, melanoma, and glioma, but these genes may be responsible for the invasion of BRCA cells. Decreased expression of genes, such as TNFRSF10B [210] , MIA2 [215] , and BBC3 [216] , are answerable for the progression of various cancers, such as lung cancer, hepatocellular carcinoma, head, and neck cancer, but low expression of these genes may be responsible for the development of BRCA. Genes, such as OAS2 [217] , ULBP1 [218] , HERPUD1 [219] , and CASP4 [220] , are diagnosed with the growth of various cancers, such as oral cancer, cervical cancer, and gliomas, but these genes may identify with the development of BRCA. SNP in genes, such as PPP1R15A [221] , PLA2G4C [222] , CMTM8 [223] , and IFNL3 [224] , are responsible for the growth of various cancers, such as colorectal cancer, osteosarcoma, and hepatocellular carcinoma, but SNP in these genes may be associated with the pathogenesis of BRCA. Mutation in UVRAG [225] and RNF43 [226] is liable for the advancement of various cancers, such as gastric cancer, colorectal, and endometrial cancers, but variation in these genes may be linked with the advancement of BRCA. Methylation inactivation of tumor suppressor ST6GAL1 [227] is responsible for the pathogenesis of bladder cancer, but the loss of this gene may be associated with the development of BRCA. Genes, such as CEBPB [228] [258] , and NAMPT [259] , are responsible for the pathogenesis of BRCA. Elevated levels of SQSTM1 have been demonstrated in oncogenesis and resistance to cancer chemotherapy. SQSTM1 regulates autophagy and apoptosis and acts as a signaling hub, which regulates cell viability in response to cytotoxic stress, thus playing a vital role in cancer. SQSTM1 is a key component and player in VANGL2-JNK signaling pathway and this signaling pathway is associated with the proliferation of breast cancer cells [260] . Pleiotropic cytokine TNFα is associated with tumor cell growth, invasion, and metastasis. TNFα plays a vital role in the progression of triple negative breast cancer (TNBC) via up-regulation of TNFAIP3. Pleiotropic DNA damage response protein, such as BRCA1, operates in both checkpoint activation and DNA repair. In our study, survival analysis revealed that high expression of BRCA1 was linked with breast cancer.
PDE2A, IFI30, VLDLR, RSAD2, IL21R, OASL, IL3RA, MX1, CYBA, ISG20, SLC27A1, OAS1, RELB, CLGN, DNAJB9, DNAJC10, SDR16C5, APOL2, COL16A1, ERO1B, STARD4, ERO1A, RDH16, PLPP3, CERS1, SLC36A1, INSIG1, BDKRB1, LPIN1, SEC24D, NFE2L1, GPAT3, HS1BP3, FADS3, SLC33A1, RELB, VSTM1, and IFNL2 are identified as novel molecular markers for the pathogenesis of BRCA in these GO category.
In PPI network, hub genes (up-regulated), such as MCM2, CDK2, HIST1H3F, HIST1H3B, TCF4, ASPM, CHST8, KCNB1, CFH, FLNA, and BRCA1, are identified with high node degree, high betweenness, high stress, and high closeness. CFH is important for the development of lung cancer [261] , but this gene may be associated with the progression of BRCA. Hub genes, such as OLR1, CHST8, KLF8, CFH, and XAGE2, are identified with the lowest clustering coefficient. XAGE2 is identified as a novel molecular marker for the pathogenesis of BRCA. While hub genes (down-regulated), such as HSPA5, MAPK6, MAP1LC3B, SQSTM1, SDCBP, ISG15, ICAM1, and NDRG1, are identified with high node degree, high betweenness, high stress, and high closeness. Genes, such as MAP1LC3B [262] , MAPK6 [263] , and NDRG1 [264] , are responsible for the development of BRCA. Hub genes, such as NEU1, BRI3, SLC27A1, DDIT4, and CXCL1, are identified with the lowest clustering coefficient. DDIT4 and BRI3 are identified as novel molecular markers for the pathogenesis of BRCA.
In module analysis, hub genes(up-regulated), such as HIST1H1B, E2F1, POLD1, CDT1, MCM3, MYBL2, CDK2, CCNE1, CDC25A, PCNA, RAD51, BLM, MSH6, BARD1, BRCA1, POLA1, RFC3, RFC5, RFC2, DSCC1, MCM10, CDC7, MCM4, MCM2, MCM6, and LMNB1, are identified in all four modules. HIST1H1B is identified as a novel molecular marker for the pathogenesis of BRCA. MCM4 is associated with the pathogenesis of BRCA [265] . Meanwhile, hub genes (down-regulated), such as HSPA5, HSPA6, MAP1LC3B, RELB, ISG15, IFIT1, IFIT2 and IFIT3, TNFRSF10B, TNFSF10, TNFAIP3, BIRC3, GBP2, SAT1, and MVD, are identified in all four modules. HSPA6, MAFF, MAFG, and SAT1 are identified as novel molecular markers for the pathogenesis of BRCA.
In target genes-miRNA network, target genes (up-regulated), such as IGFBP5, RAD51, DSN1, RRM2, and ZWINT, are identified with a high degree. Expression of IGFBP5 is responsible for the development of BRCA [266] . Meanwhile, target genes (down-regulated), such as SOD2, DNAJC10, PEG10, LDLR, and RORA, are identified with a high degree. Genes, such as SOD2 [267] , and PEG10 [268] , are associated with the pathogenesis of BRCA. LDLR is responsible for the advancement of prostate cancer cells [269] , but this gene may be associated with the development of BRCA.
In target genes-TF network (up-regulated), target genes, such as DHFR, TBXAS1, MCEE, ETNK2, and CENPM, are identified with a high degree. TBXAS1 is responsible for the development of BRCA [270] . MCEE and ETNK2 are identified as novel molecular markers for the pathogenesis of BRCA. Meanwhile, target genes (down-regulated), such as MT1H, KRTAP5-4, RETN, HSD17B14, and SEPHS2, are identified with a high degree. KRTAP5-4 and HSD17B14 are identified as novel molecular markers for the pathogenesis of BRCA.
Survival analysis revealed that genes, such as BRCA1, FLNA, FLNB, HSPA5, MAP1LC3B, NDRG1, PCNA, and TUBB2B, are predicting longer survival of BRCA, while genes, such as HIST1H3B and MAPK6, are predicting shorter survival of BRCA. High expression of genes, such as BRCA1, HIST1H3B, MAPK6, NDRG1, and PCNA, is linked with BRCA; while low expression of genes, such as FLNA, FLNB, HSPA5, MAP1LC3B, and TUBB2B, are linked with BRCA.
Conclusions
In this study, key genes were identified for the first time in estradiol and tamoxifen drug-treated BRCA by integrated bioinformatics analysis. By analyzing the pathway and GO enrichment analysis, we found that DEGs were mainly enriched in the lysine degradation II (pipecolate pathway), cholesterol biosynthesis, cell cycle, and response to cytokine, which provide a theoretical basis for studying the biological processes of BRCA. We successfully constructed a PPI network, miRNA-target gene regulatory network, and TF-target gene regulatory network of DEGs in BRCA and screened several key genes encoding proteins in the networks that are associated in the process of BRCA in the form of molecular populations. These findings promote our understanding of the molecular pathogenesis of BRCA during estradiol and tamoxifen drug treatment and may provide an enhanced perceptive of the molecular mechanisms that underlie breast cancer. However, further molecular biological experiments are required to confirm the action of the diagnosed genes that are linked with BRCA during estradiol and tamoxifen drug treatment.
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